On June 18, Scott Wren, Wells Fargo senior global market strategist, joined CNBC’s ‘Closing Bell Overtime’ to talk about how the market sell-off is an opportunity to step in. Wren discussed the market’s performance and noted that the major averages closed down nearly a percent, with the NASDAQ faring the worst. He clarified that this reaction is not due to the lower 10-year Treasury yield but rather attributed it partly to the price of oil. He explained that a jump in oil prices, potentially to $90 or $100 a barrel, would negatively impact the market.
He suggested that after a strong run since the April lows, some investors are taking a little bit of money off the table. Wren advised against this move and recommended favoring developed international markets over emerging markets. However, Wells Fargo Investment Institute has a long-standing preference for US assets and considers them to be of better quality due to the US economy’s greater innovation compared to the European economy.
That being said, we’re here with a list of the 11 best mid cap growth stocks to invest in now.
A portfolio manager in front of their computer screen, evaluating a variety of mid-cap stocks.
Methodology
We sifted through financial media reports to compile a list of the top growth stocks trading between $2 billion and $10 billion. We then selected 11 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q1 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11 Best Mid Cap Growth Stocks To Invest In Now
11. Super Group Limited (NYSE:SGHC)
Market Capitalization as of June 19: $4.90 billion
Number of Hedge Fund Holders: 22
Super Group Limited (NYSE:SGHC) is one of the best mid cap growth stocks to invest in now. Earlier on June 11, BTIG analyst Clark Lampen increased the price target for Super Group to $11 from $9, while reiterating a Buy rating on the shares. This adjustment reflects BTIG’s updated financial model, which incorporates Super Group’s recent change in presentation currency and a more favorable outlook for its Sportsbook operations in FY2025 and FY2026.
In Q1 2025, Super Group’s total revenue reached an all-time high of $517 million, which marked a 25% increase year-over-year. Revenue excluding the US market was $502 million, which was up 24% year-over-year. The company’s unique monthly active customers averaged 5.4 million for the quarter, which was a 14% increase from 4.7 million in Q1 2024.
Specifically, sports betting grew 7% while casino operations saw a 23% increase. Geographically, Africa’s revenue grew by 54% due to strong performance in South Africa, Ghana, Malawi, and the successful launch in Botswana. European revenue increased by 53%, with the UK market showing particularly strong growth of 87% due to the performance of Jackpot City and Betway. Canada’s revenue also grew by 13%. However, the APEC region experienced a 13% decline due to currency weakness and the closure of non-performing markets.
Super Group Limited (NYSE:SGHC) operates as an online sports betting and gaming operator.
10. TransMedics Group Inc. (NASDAQ:TMDX)
Market Capitalization as of June 19: $4.30 billion
Number of Hedge Fund Holders: 23
TransMedics Group Inc. (NASDAQ:TMDX) is one of the best mid cap growth stocks to invest in now. On June 17, Oppenheimer increased the price target for TransMedics to $150 from $130, while maintaining an Outperform rating on the shares. This adjustment came after the OrganOx Metra device had its air transport warning removed from its label on June 2. The OrganOx Metra device is a competitor in the organ preservation market.
Despite mixed outcomes from field checks on the Metra device, OrganOx continues to receive positive feedback from the Organ Procurement Organization community. Oppenheimer expects that the OrganOx Metra device will likely gain market share in DCD/Donation after Circulatory Death liver transplants. This is attributed not necessarily to superior outcomes compared to TransMedics’ technology, but rather to a perceived strained relationship between TransMedics and the OPOs.
In Q1 2025, TransMedics achieved a record total revenue of $143.5 million, which showed a 48% year-over-year growth compared to $96.9 million in Q1 2024. Transplant services revenue specifically saw a 56% increase due to higher utilization of their OCS NOP/Organ Care System National Organ Preservation platform. TransMedics also raised its full-year 2025 revenue guidance to a range between $565 and $585 million, which represents a 30% growth at the midpoint.
TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company that transforms organ transplant therapy for end-stage organ failure patients internationally.
Hedge Fund Resource Center